Page 202 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Chapter 7
Table S2. Central pathology review data on 85 MYC+ LBCL patients treated with R2CHOP.
Patient number
Eligible
CD20
0= negative (<95%), 1=positive (>95%)
BCL2 0=negative (<50%), 1=positive (50%), 9=not available
MYC-IHC 0=negative (<40%), 1=positive (>40%), 9=not available
CD10 0=negative, 1=positive, 9=not available
BCL6 0=negative (<40%), 1=positive (>40%), 9=not available
1 yes 2 yes 3 yes 4 yes 5 yes 6 yes 7 yes 8 no 9 no 10 yes 11 yes
12 yes 13 yes
14 yes 15 yes 16 yes 17 yes 18 yes 19 yes 20 yes 21 yes 22 yes 23 yes 24 yes 25 yes
26 yes
27 yes 28 yes
29 yes 30 yes 31 yes 32 yes 33 yes 34 yes 35 yes
36 yes 37 yes
38 yes
Immunohistochemistry
1 0 1 1 1 1 1 9 0 1 1 1 9 1 1 1 1 0 1 1 1 1 9 1 1 1 1 1 1 1 1 0 9 1 1
1 1 1 1 1 1 0 1 1 9
1 0 1 1 1 1 1 1 1 1
1 1 9 1 1 1 1 1 9 9 1 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1
1 1 0 1 1 1 1 9 1 1 1 1 1 0 1 1 1 1 0 1
1 1 9 0 1
1 1 9 1 1 1 0 1 1 1
1 0 1 0 1 1 1 0 1 1 1 1 0 0 1 1 1 1 1 1 1 1 1 1 0 1 0 1 1 1 1 1 9 1 1
1 0 1 1 1 1 0 9 1 1
1 0 1 1 0
200